AUCTORES
Globalize your Research

Journal of Thoracic Disease and Cardiothoracic Surgery
Tamer A. Addissouky *

Open Access

Review Article

Towards Personalized Care: Unraveling the Genomic and Molecular Basis of Sepsis-Induced Respiratory Complications

Tamer A. Addissouky [1,2,3]*, Ibrahim El Tantawy El Sayed [2], Majeed M. A. Ali [1], Yuliang Wang [4], and Ahmed A. Khalil [5]

[1]Al-Hadi University College, Baghdad, Iraq.

[2]Department of Biochemistry, Science Faculty, Menoufia University, Menoufia, Egypt

[3]MLS ministry of health, Alexandria, Egypt. - MLS ASCP, USA.

[4]Joint International Research Laboratory of Metabolic and Developmental Sciences, Key Laboratory of Urban Agriculture (South) Ministry of Agriculture, Plant Biotechnology Research Center, Fudan-SJTU-Nottingham Plant Biotechnology R&D Center, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China.

***Corresponding Author:** Tamer A. Addissouky, Al-HADI University College, Baghdad. Iraq. - Department of Biochemistry, Science Faculty, Menoufia University, Egypt. - MLS ministry of health, Alexandria, Egypt. - MLS, ASCP, USA.

Received date: January 18, 2024; Accepted date: February 05, 2024; Published date: February 23, 2024

Citation: Tamer A. Addissouky, Ibrahim El Tantawy El Sayed, Majeed M. A. Ali, Yuliang Wang, and Ahmed A. Khalil, (2024), Towards Personalized Care: Unraveling the Genomic and Molecular Basis of Sepsis-Induced Respiratory Complications, *J Thoracic Disease and Cardiothoracic Surgery*, 5(2); **DOI:10.31579/2693-2156/081**

Abstract

Background: Sepsis is a life-threatening condition causing significant morbidity and mortality worldwide. Respiratory dysfunction is a common and serious complication of sepsis. Elucidating the intricate mechanisms underlying sepsis-induced respiratory complications is crucial for improving patient outcomes.

Purpose: This review provides a comprehensive overview of recent advances across the epidemiology, pathogenesis, clinical management, and diagnostic approaches pertaining to sepsis-related respiratory dysfunction.

Main body: Sepsis triggers both direct lung injury from pathogens as well as indirect systemic inflammation mediated by cytokines, immune cells, and vascular changes. These convergent mechanisms can lead to acute respiratory distress syndrome (ARDS) and other hypoxemic complications. Certain populations like the elderly and those with chronic illnesses are at higher risk. Timely antibiotic therapy and hemodynamic stabilization are essential to prevent respiratory deterioration. Supportive ventilation strategies and adjuvant treatments like prone positioning may be employed for severe cases. Ongoing research has focused on modulating inflammatory and molecular targets involved in lung injury as potential preventive approaches. Emerging tools utilizing genomics, biomarkers, and artificial intelligence hold promise for early risk assessment, diagnosis, and personalized treatment strategies.

Conclusion: This review highlights recent advances across the spectrum of sepsis-induced respiratory dysfunction. Integrating molecular mechanisms with clinical translation and leveraging new technologies is key to improving early detection, optimizing management, and ultimately reducing the burden of sepsis-related respiratory morbidity and mortality.

Keywords: sepsis; acute respiratory distress syndrome (ARDS); antimicrobial timing; AI; biomarkers

Introduction

Sepsis, a life-threatening syndrome characterized by organ dysfunction, is a global health concern with alarmingly high morbidity and mortality rates [1]. In understanding sepsis, particularly its association with respiratory complications, we gain valuable insights into improving patient outcomes [2]. Early detection of sepsis-induced respiratory complications plays a critical role in guiding clinical management and

treatment strategies. In this comprehensive overview, we delve into the epidemiology, pathogenesis, clinical management, and future directions pertaining to biomarkers and diagnostic tools for early detection of sepsis-induced respiratory complications. Sepsis, often triggered by a severe infection, leads to a dysregulated immune response and organ dysfunction [3]. Its association with an alarming rate of morbidity and mortality emphasizes the urgent need for effective diagnostic tools and timely intervention. By understanding the intricate nature of sepsis as a syndrome causing life-threatening organ dysfunction, we can unravel its complex respiratory complications. Sepsis poses a significant burden on global health, accounting for a substantial number of hospital admissions and healthcare costs [4]. The prevalence of sepsis-induced respiratory complications, such as acute respiratory distress syndrome (ARDS), further intensifies the gravity of the situation. Identifying risk factors that contribute to the development of respiratory complications in sepsis patients enables targeted interventions and improved patient care [5]. Unveiling the mechanisms underlying respiratory complications in sepsis is fundamental in advancing diagnostic and therapeutic approaches. Cytokines, chemokines, and immune cells contribute to respiratory dysfunction, requiring a deeper understanding of both direct and indirect injuries involved [6]. Timely treatment of underlying sepsis is essential to prevent or mitigate respiratory complications. Early identification of patients at risk of developing respiratory complications allows targeted interventions and better prognostic outcomes [7]. Current treatment strategies, along with emerging preventive approaches based on molecular and genetic research, hold promise for improved patient care. Identifying biomarkers and developing diagnostic tools creates opportunities for early detection and prognosis of sepsis-induced respiratory complications [8]. Gene biomarker panels hold potential to revolutionize diagnosis, allowing for swift intervention and personalized treatment strategies. Network analysis and bioinformatics further aid in biomarker discovery, facilitating a comprehensive understanding of sepsis pathogenesis [9]. The international guidelines for sepsis and septic shock management, such as the Surviving Sepsis Campaign, provide a standardized approach to clinical management [10]. Emphasizing the importance of timely administration of antimicrobials and their association with mortality rates, these guidelines also provide recommendations for managing sepsis-induced respiratory complications [11]. Recapping the key findings and insights on respiratory complications in sepsis, we recognize the need for further research to unravel the intricacies of pathogenesis and develop novel therapies [12]. Integrated approaches combining molecular research and clinical translation hold immense potential in transforming sepsis management, improving patient outcomes, and ultimately reducing the global burden of sepsis-induced respiratory complications [13-16].

While prior reviews have examined respiratory complications in sepsis, this article provides a comprehensive overview of recent advances across pathogenesis, risk factors, clinical management, and emerging diagnostic biomarkers and tools. The review offers novel insights into the intricate mechanisms underlying sepsis-induced respiratory dysfunction. It emphasizes the importance of early identification of patients at risk to enable targeted preventive strategies and personalized treatments.

I. Sepsis and its Association with High Morbidity and Mortality Rates

Sepsis is a complex syndrome with varying manifestations, making its definition crucial for diagnosis and treatment. The association between sepsis and high morbidity and mortality rates is well-established, emphasizing the importance of timely recognition and intervention. In this review, we will delve into the definition of sepsis and explore its implications on morbidity and mortality rates [17]. The definition of sepsis has evolved over the years to improve accuracy and enhance clinical management. According to Sepsis-3, sepsis is now defined as a dysregulated host response to infection, resulting in life-threatening organ dysfunction. This definition places emphasis on organ dysfunction rather than just infection and incorporates clinical and laboratory parameters for identification [18]. Sepsis often leads to a range of complications and long-term consequences, contributing to its high morbidity rates. Organ dysfunction caused by sepsis can result in multi-organ failure, leading to prolonged hospital stays, increased risk of secondary infections, and the development of chronic health conditions. Additionally, sepsis survivors often experience long-lasting physical, emotional, and cognitive impairments, impacting their quality of life [19]. Sepsis remains a significant global public health concern due to its high mortality rates. Despite advances in medical care, sepsis-associated mortality remains alarmingly high. Studies have shown that early recognition and timely intervention greatly affect patient outcomes [20]. However, delayed or inappropriate therapy can escalate organ dysfunction, culminating in septic shock, which significantly increases the risk of death. Additionally, certain patient populations, such as the elderly, immunocompromised individuals, and those with pre-existing conditions, are particularly vulnerable to sepsis-related mortality [21].

II. Sepsis through unlocking the Understanding of a Life-Threatening Syndrome

Sepsis, a potentially fatal medical condition, is a syndrome that triggers widespread inflammation and organ damage throughout the body. Recognizing the importance of understanding sepsis and its devastating consequences is crucial for medical professionals and the general public alike. In this review, we delve deep into the complexities of sepsis,

exploring its causes, symptoms, diagnostic techniques, and life-saving treatments [22]. Sepsis is often referred to as the body's extreme response to an infection. Although infections can be caused by various sources such as bacteria, viruses, fungi, or parasites, sepsis occurs when the immune system's response goes haywire, leading to severe complications. This cascading response leads to widespread inflammation and dysfunctional organ behavior, ultimately posing a severe threat to the patient's life [23]. Sepsis can be triggered by infections stemming from various sources, including pneumonia, urinary tract infections, abdominal infections, or skin infections. Additionally, individuals with weakened immune systems, chronic illnesses, or those undergoing invasive medical procedures are at an increased risk for developing sepsis. Early recognition and prompt treatment are crucial to preventing its progression [24]. Recognizing the symptoms of sepsis is vital for timely intervention. Common indicators include fever, rapid heart rate, breathing difficulties, disorientation, decreased urine output, and a significant drop in blood pressure. A comprehensive diagnostic approach combines physical examination, blood cultures, imaging tests, and measurement of biomarkers to confirm sepsis and its severity [25]. Sepsis primarily damages vital organs, such as the lungs, heart, kidneys, liver, and brain, as a result of blood circulation impairment and inadequate oxygen delivery [26-34]. This dysfunction can potentially lead to acute respiratory distress syndrome (ARDS), myocardial dysfunction, acute kidney injury (AKI), liver dysfunction, and neurological complications [35-36]. The severity of organ dysfunction determines the patient's prognosis and guides the intensity of medical interventions [37].

III. Importance of understanding the relationship between sepsis and respiratory complications

The respiratory system acts as a gateway for pathogens, making it particularly susceptible during cases of sepsis. The compromised immune response allows microorganisms to invade the lower respiratory tract, leading to respiratory complications such as pneumonia, acute respiratory distress syndrome (ARDS), and ventilator-associated pneumonia (VAP). Understanding the bidirectional relationship between sepsis and respiratory complications is paramount. While sepsis can lead to respiratory problems, it is equally important to recognize how respiratory conditions can predispose individuals to sepsis. Conditions such as chronic obstructive pulmonary disease (COPD), pneumonia, and ventilator-associated lung injury can serve as potential triggers for sepsis, accentuating the need for early intervention [38]. The intertwining relationship between sepsis and respiratory complications can be attributed to shared pathophysiological mechanisms [39]. Inflammatory mediators, endothelial dysfunction, alveolar damage, impaired gas exchange, and the activation of coagulation pathways play pivotal roles in both sepsis and respiratory dysfunction. Understanding these mechanisms can provide clinicians with the knowledge necessary for accurate diagnosis and tailored therapeutic interventions [40]. Recognizing the relationship between sepsis and respiratory complications is crucial for timely and appropriate medical intervention [41]. Early identification, immediate administration of appropriate antibiotics, ventilatory support, hemodynamic stabilization, and infection control measures are pivotal in enhancing patient outcomes and reducing mortality rates [42-43].

IV. Epidemiology and Risk factors for developing respiratory complications in sepsis patients

The global burden of sepsis is significant, with more than 19 million sepsis cases and 5 million sepsis-related deaths estimated to occur annually. The majority of sepsis cases and deaths occur in low and middle-income countries. Epidemiology is crucial for understanding the distribution and determinants of sepsis, including risk factors, incidence, and mortality rates [44]. Respiratory complications are a common and serious consequence of sepsis, and identifying the risk factors. Sepsis is most commonly caused by infections, such as pneumonia, urinary tract infections, and skin infections. These infections can directly or indirectly lead to respiratory complications. Older adults are more susceptible to respiratory complications in sepsis due to age-related changes in the immune system and a higher prevalence of comorbidities. The severity of sepsis, including the presence of septic shock, is associated with an increased risk of developing respiratory complications [45]. In some cases, pneumonia or other lung infections can directly injure the lungs and lead to respiratory complications. Sepsis can cause indirect injury to the lungs through the release of inflammatory mediators, leading to lung inflammation and subsequent respiratory complications. Smoking is a risk factor for respiratory complications in sepsis patients, as it can worsen lung function and increase the risk of lung injury. Alcohol abuse can weaken the immune system and increase the risk of respiratory complications in sepsis patients. Patients with pre-existing chronic health conditions, such as diabetes, cancer, and kidney disease, are at a higher risk of developing respiratory complications in the setting of sepsis [46].

V. Pathogenesis of Sepsis-Induced Respiratory Complications

Sepsis is a life-threatening condition caused by the body's response to an infection. It can lead to respiratory complications and organ failure.

V.1. Mechanisms underlying the development of respiratory complications in sepsis

Sepsis triggers a cascade of complex inflammatory responses in the body. When the body detects infections, the immune system releases cytokines to help fight the infection as depicted in **table 1**. However, in severe cases of sepsis, the immune response becomes uncontrolled and dysregulated,

leading to a cytokine storm. The overproduction of pro-inflammatory cytokines like interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) contributes to the pathological changes in sepsis. This cytokine storm can damage the lungs and airways in sepsis patients, causing respiratory complications. The pro-inflammatory cytokines can activate neutrophils and cause them to accumulate in the lungs, resulting in acute lung injury and acute respiratory distress syndrome (ARDS). This neutrophil infiltration worsens pulmonary edema and inflammation [47]. The cytokine storm also increases microvascular permeability in the lungs, leading to leakage of fluids into the air spaces and impairment of gas exchange. The fluid buildup in the alveolar air spaces and interstitium further exacerbates pulmonary edema and hypoxemia in sepsis patients. The pro-inflammatory mediators produced during sepsis impair the function of pulmonary surfactant, a mixture of proteins and lipids that helps keep the alveoli open. Decreased production and inactivation of surfactant contribute to atelectasis formation and worsened lung compliance in sepsis. Increased mucus secretion from the goblet cells of the airway epithelium also occurs during sepsis, narrowing the airway lumen and making breathing difficult. This mucus plugging, together with microatelectasis from surfactant dysfunction, impedes oxygenation and gas exchange in the lungs. All of these pathological changes mediated by the cytokine storm can lead to sepsis-induced respiratory complications like ARDS, pneumonia, and other types of hypoxemic respiratory failure. The mechanisms mentioned aim to provide insight into the complex pathogenesis behind these serious lung complications in sepsis [48]. Acute respiratory distress syndrome (ARDS) can develop as a consequence of sepsis originating from either a direct lung infection or an indirect extrapulmonary source. In both scenarios, the host immune response to the inciting pathogen results in a cascade of inflammatory events that ultimately disrupt the integrity of the alveolar-capillary barrier in the lungs. This barrier is formed by the lining of the alveoli (epithelial cells) and the adjacent capillary endothelium. When sepsis triggers inflammatory cells like neutrophils and macrophages to accumulate in the lungs, they release a flood of proinflammatory signaling molecules called cytokines. Additionally, the immune system recognizes pathogen- and damage-associated molecular patterns through pattern recognition receptors. These manifold signaling pathways converge to inflict injury to the alveolar and capillary cells. The ensuing loss of barrier integrity enables an influx of protein-rich edema fluid into the airspaces, producing the hallmark pulmonary edema seen in sepsis-induced ARDS. Therefore, regardless of the sepsis source, an uncontrolled inflammatory response damages the crucial alveolar-capillary membrane, leading to life-threatening lung injury and respiratory failure as represented in **figure 1** [49].



Figure 1: From Infection to Inflammation to Injury: The Multifactorial Pathogenesis of Sepsis-Associated ARDS [49].

Mechanism	Description
Cytokine storm	Excessive release of pro-inflammatory cytokines like IL-1, IL-6, and TNF-α; contributes to increased vascular permeability, impaired surfactant function, lung epithelium damage
Neutrophil infiltration	Chemokines activate and recruit neutrophils to lungs; release proteolytic enzymes and reactive oxygen species that damage lung tissue
Macrophage activation	Alveolar macrophages produce more pro-inflammatory cytokines, amplifying cytokine storm and lung inflammation
Surfactant dysfunction	Cytokines impair surfactant production and function; contributes to atelectasis and decreased lung compliance

Table 1: Key mechanisms underlying sepsis-induced respiratory complications

V.2. Role of cytokines, chemokines, and immune cells in respiratory dysfunction

Sepsis leads to an uncontrolled inflammatory response that damages the lungs and causes respiratory complications. Cytokines, chemokines, and immune cells work together to drive this pathological process [50]. Cytokines like IL-1, IL-6 and TNF-α are overproduced during the sepsis-induced cytokine storm. They increase vascular permeability, impair surfactant function, and damage the lung epithelium [51]. This contributes to acute lung injury and dysfunction. While anti-inflammatory cytokines like IL-10 also rise, they fail to balance the effects of pro-inflammatory cytokines [52]. Chemokines are released that recruit neutrophils and other immune cells to the lungs. Chemokines like IL-8 activate and migrate neutrophils, exacerbating lung inflammation [53]. Neutrophils accumulate in large numbers in the lungs due to cytokines and chemokines. The activated neutrophils release proteolytic enzymes and reactive oxygen species that oxidize lipids and proteins, damaging lung tissues and worsening injury [54]. Macrophages in the alveolar space are also activated during sepsis and produce more pro-inflammatory cytokines. They amplify the cytokine storm and promote persistent lung inflammation [55]. Intravenous immunoglobulin (IVIG) therapy has potential roles in modulating the dysregulated immune response in sepsis and septic shock. IVIG contains antibodies like IgG, IgM, and IgA that can interact with various components of the innate and adaptive immune system. Experimental evidence indicates IVIG can neutralize toxins, opsonize pathogens, activate complement, and regulate pro- and anti-inflammatory cytokines. Particular formulations enriched in IgM and IgA have shown promise in pneumonia and toxic shock syndrome **figure 2** [56].



Figure 2: The Unrealized Promise of IVIG as an Immunomodulator in Sepsis [56].

V.3. Differentiating direct and indirect injuries in sepsis-induced respiratory complications

Direct injuries in sepsis-induced respiratory complications refer to the damage inflicted directly on the lungs by the infection itself. When the infection enters the lungs, it can lead to inflammation and tissue damage, impairing the ability of the lungs to efficiently exchange oxygen and carbon dioxide. This can result in respiratory distress, characterized by symptoms such as rapid breathing, shortness of breath, and low oxygen levels. Direct injuries can also lead to the development of conditions like pneumonia or acute respiratory distress syndrome (ARDS), further exacerbating respiratory complications in sepsis [57].

Indirect injuries, on the other hand, are not caused directly by the infection but rather by the body's response to the infection. During sepsis, the immune system goes into overdrive, releasing excessive amounts of inflammatory molecules called cytokines. These cytokines can cause widespread inflammation throughout the body, including the lungs. This inflammation can lead to injury and dysfunction of the lung tissues, contributing to respiratory complications. Indirect injuries may result in conditions such as acute lung injury and ARDS, where the lungs become stiff and cannot effectively oxygenate the blood [58].

Distinguishing between direct and indirect injuries in sepsis-induced respiratory complications can be challenging due to their overlapping features. Both types of injuries can cause similar symptoms, such as difficulty breathing and low oxygen levels. However, there are some key differences that can help in their differentiation. Direct injuries are commonly associated with infections localized in the lungs, and imaging studies such as chest X-rays or CT scans may reveal signs of pneumonia or lung consolidation. Indirect injuries, on the other hand, are typically characterized by a systemic inflammatory response affecting multiple organs, including the lungs [59].

Clinical evaluation and monitoring play a crucial role in differentiating between direct and indirect injuries. Healthcare providers may assess the patient's medical history, conduct a thorough physical examination, and order various diagnostic tests to identify the underlying cause of respiratory complications in sepsis. Blood tests can help determine markers of infection, inflammation, and organ dysfunction. Imaging studies may reveal specific lung abnormalities, aiding in the diagnosis. Additionally, advanced techniques such as bronchoscopy or lung tissue biopsy may be performed in certain cases to confirm the presence and nature of injuries [60].

Accurately distinguishing between direct and indirect injuries in sepsis-induced respiratory complications is essential for guiding appropriate treatment strategies. While both types of injuries contribute to respiratory compromise, their management approaches may differ. Direct injuries often require targeted antibiotic therapy to combat the underlying infection, along with supportive care to optimize lung function. Indirect injuries, on the other hand, focus on controlling the systemic inflammatory response through interventions like fluid management, vasopressor support, and corticosteroids. Individualized treatment plans should be tailored based on the underlying cause and severity of respiratory complications [61].

IV. Clinical Management and Treatment

IV.1. Timely treatment of underlying sepsis to prevent or mitigate respiratory complications

In sepsis, the immune response to an infection can lead to the release of chemicals into the bloodstream, causing widespread inflammation. This inflammatory response can impact the functions of various organs, including the lungs. If left untreated or if treatment is delayed, sepsis can progress to severe sepsis, where organ dysfunction becomes evident. Respiratory complications, such as acute respiratory distress syndrome (ARDS), are common in severe sepsis and can contribute to a higher risk of mortality [62]. Early identification and treatment of sepsis are crucial to prevent the progression of the condition and the subsequent development of respiratory complications. Healthcare professionals play a vital role in recognizing the signs and symptoms of sepsis, such as fever, increased heart rate, rapid breathing, and altered mental status. Once sepsis is suspected, prompt action should be taken to initiate appropriate treatment [63]. Timely treatment of underlying sepsis involves a multifaceted approach. The first step is identifying the source of infection, which may require various diagnostic tests, including blood cultures, imaging studies, and urine or sputum analysis. Antibiotics are administered promptly to target the specific infection causing the sepsis. This early administration of antibiotics is crucial in preventing the infection from spreading and reducing the overall inflammatory response [64].

Alongside antibiotic therapy, supportive care is essential in managing sepsis and preventing respiratory complications. Adequate fluid resuscitation helps maintain blood pressure and organ perfusion. Additionally, oxygen therapy may be necessary to support respiratory function and prevent hypoxia. In severe cases, mechanical ventilation might be required to ensure sufficient oxygenation and ventilation. It is worth noting that appropriate treatment should not only focus on managing the acute symptoms but also on addressing any underlying conditions that may have predisposed the patient to sepsis. Identifying and treating the root causes, such as pneumonia or urinary tract infections, can aid in preventing recurrences or the development of chronic conditions [65].

IV.2. Current treatment strategies for sepsis-induced respiratory complications

In recent years, there have been significant advancements in the treatment strategies for sepsis-induced respiratory complications as depicted in **table 2**.

Preventive Strategy	Description
Targeting molecular mechanisms	Developing therapies to modulate cytokines, chemokines and other molecules involved in lung inflammation and injury
Genetic risk assessment	Identifying gene variants that predispose patients to respiratory complications, enabling early prevention
Biomarker monitoring	Tracking biomarkers to predict and mitigate lung injury progression
Immunomodulation	Restoring immune homeostasis using checkpoint inhibitors, stem cells to prevent excessive inflammation

Table 2: Emerging preventive strategies for sepsis-induced respiratory complications

IV.2.1. Early recognition and prompt treatment:

Early recognition and timely initiation of treatment are crucial in managing sepsis-induced respiratory complications. This involves identifying the signs and symptoms of sepsis early on and initiating appropriate interventions promptly. This includes administering antibiotics, ensuring adequate fluid resuscitation, and providing respiratory support if necessary [66].

IV.2.2. Antibiotic therapy:

In sepsis-induced respiratory complications, prompt administration of appropriate antibiotics is essential. Broad-spectrum antibiotics are often initiated empirically until culture results guide the selection of targeted antibiotics. The choice of antibiotic depends on the suspected source of infection and the local antimicrobial resistance patterns [67].

IV.2.3. Hemodynamic support:

Sepsis-induced respiratory complications can lead to hemodynamic instability and organ dysfunction. Hemodynamic support is a key component of treatment, which involves maintaining adequate blood pressure, optimizing fluid balance, and using vasopressor medications to support cardiac output in severe cases [68-69].

IV.2.4. Mechanical ventilation and supportive care:

In patients with severe respiratory compromise, mechanical ventilation is often necessary. Lung-protective ventilation strategies, which aim to minimize further lung injury, are employed. Positive end-expiratory pressure (PEEP) is used to improve oxygenation and recruit collapsed lung regions. Supportive care includes close monitoring of fluid balance, electrolyte management, and nutritional support [70].

IV.2.5. Adjunctive therapies:

Several adjunctive therapies have shown promise in sepsis-induced respiratory complications. These include prone positioning, which improves oxygenation in ARDS patients by redistributing lung perfusion [71]. Extracorporeal membrane oxygenation (ECMO) may be considered in refractory cases as a bridge to recovery or lung transplantation [72].

IV.2.6. Targeted therapies:

Recent research has focused on identifying specific targets in the inflammatory cascade of sepsis-induced respiratory complications. Agents such as corticosteroids, anti-inflammatory cytokines, and mesenchymal stem cells are being studied for their potential to modulate the immune response and improve outcomes [73].

IV.2.7. Supportive management:

Alongside these targeted treatment strategies, supportive management plays a critical role in optimizing outcomes. This includes ensuring appropriate pain control, preventing complications like pressure ulcers and deep vein thrombosis, and managing any concurrent infections or organ dysfunctions [74].

IV.3. Emerging preventive strategies based on molecular and genetic research

There has been a growing focus on molecular and genetic research to develop innovative preventive strategies for sepsis-induced respiratory complications, delving into seven key emerging preventive strategies [75]. Firstly, one promising approach involves targeting the molecular mechanisms underlying sepsis-induced lung injury [76]. Extensive research has identified various molecules, such as cytokines and chemokines that play critical roles in the inflammatory response during sepsis. By developing targeted therapies to modulate the expression or activity of these molecules, it may be possible to attenuate lung damage and improve respiratory outcomes [77]. Secondly, genetic research has shed light on the genetic predisposition to sepsis and its complications. Identifying specific genetic markers associated with an increased susceptibility to respiratory complications in sepsis patients could enable early risk assessment and personalized preventive strategies [78]. Advances in genome-wide association studies and gene sequencing technologies have contributed significantly to this field, offering valuable insights into the genetic determinants of sepsis-induced lung injury [79]. Thirdly, the use of biomarkers holds great promise in predicting and preventing sepsis-induced respiratory complications. Biomarkers are measurable indicators of physiological or pathological processes occurring within the body. By identifying specific biomarkers that are associated with the development or progression of lung injury in sepsis, clinicians can effectively monitor patients and intervene at early stages to prevent or mitigate respiratory complications [80]. Fourthly, pharmacogenomics, the study of how individual genetic variations influence responses to medications, could revolutionize sepsis management. By analyzing a patient's genetic profile, it may be possible to predict their response to specific drugs used for the prevention or treatment of sepsis-induced respiratory complications [81]. This

personalized approach could help optimize therapeutic regimens, minimize adverse effects, and enhance treatment efficacy [82-83].

Fifthly, immunomodulatory therapies offer a potential preventive strategy for reducing respiratory complications in sepsis. The dysregulated immune response in sepsis plays a crucial role in lung injury. Novel immunotherapies, such as immune checkpoint inhibitors or cell-based therapies, could modulate the immune system and restore its equilibrium, preventing excessive lung inflammation and subsequent respiratory damage [84]. Sixthly, advances in nanomedicine have opened up new possibilities for targeted drug delivery and precision medicine in sepsis-induced respiratory complications. Nanoparticles can be engineered to carry therapeutic agents specifically to the inflamed lungs, maximizing treatment efficacy while minimizing systemic side effects. Nanotechnology-based approaches offer great potential for personalized preventive strategies in sepsis management [85]. Lastly, the emergence of artificial intelligence (AI) and machine learning is revolutionizing medical research and healthcare [86-87]. AI algorithms can rapidly analyze vast amounts of molecular and genetic data, identifying complex patterns and predicting patient outcomes [88].

V. Biomarkers and Diagnostic Tools

Recent advances in genomics offer new hope for early identification of high-risk patients through biomarker discovery as depicted in **table 3**.

Biomarker	Description
Procalcitonin (PCT)	Inflammatory marker indicating potential sepsis
KL-6	Marker of lung injury and alveolar damage
miR-15a, miR-16	MicroRNAs altered in sepsis, may serve as early diagnostic markers
F2-isoprostanes	Marker of oxidative stress involved in sepsis pathophysiology

Table 3: Biomarkers for early detection of sepsis-induced respiratory complications

Inflammatory markers: Procalcitonin (PCT), C-reactive protein (CRP), and interleukin-6 (IL-6) are commonly used inflammatory markers that can indicate the presence of sepsis. Elevated levels of these markers in the blood can help clinicians identify patients who are at risk of developing sepsis-induced respiratory complications.

Pulmonary markers: KL-6 and MMP-7 are markers of lung injury and repair, respectively. Elevated levels of these markers in the blood can help clinicians identify patients who are at risk of developing acute respiratory distress syndrome (ARDS) or other pulmonary complications.

Oxidative stress markers: F2-isoprostanes and 8-isoprostane are markers of oxidative stress, which is a key component of sepsis pathophysiology. Elevated levels of these markers can help clinicians identify patients who are at risk of developing sepsis-induced respiratory complications [89].

Cellular apoptosis markers: HSP70 and caspase-3 are markers of cellular apoptosis, which can occur in response to sepsis-induced inflammation and tissue damage. Elevated levels of these markers can help clinicians identify patients who are at risk of developing sepsis-induced respiratory complications.

MicroRNA (miRNA) markers: miRNAs are small non-coding RNAs that play a critical role in regulating gene expression. Specific miRNAs, such as miR-15a, miR-16, and miR-29b, have been altered in sepsis and may serve as potential biomarkers for early diagnosis and prognosis [90].

VI. Role of AI and network analysis and bioinformatics in biomarker discovery

Artificial intelligence (AI), network analysis, and bioinformatics are powerful tools that can aid in the discovery of new biomarkers for sepsis diagnosis and monitoring.

AI-driven biomarker discovery: Machine learning algorithms can analyze large datasets of patient information, including demographics, medical history, laboratory results, and clinical outcomes. AI can identify patterns and correlations between variables that might not be apparent to human analysts, allowing for the identification of novel biomarkers.

Network analysis: Sepsis is a complex condition involving multiple organ systems and biological pathways. Network analysis can help uncover relationships between different biological molecules, such as proteins, genes, and metabolites, and how they interact in sepsis. This approach can reveal new biomarker candidates and provide insights into the underlying mechanisms of sepsis [91].

Bioinformatics: The abundance of genomic, transcriptomic, and proteomic data offers opportunities for bioinformatic analysis. Bioinformatics tools can help identify genes or proteins that are differentially expressed between healthy individuals and those with sepsis. Additionally, bioinformatics can aid in the prediction of protein structures and functions, facilitating the understanding of molecular interactions and potential therapeutic targets.

Integration of multi-omics data: By integrating data from different omics technologies, such as genomics, transcriptomics, proteomics, and metabolomics, researchers can gain a comprehensive view of the molecular landscape of sepsis. AI and machine learning techniques can then be applied to this integrated dataset to identify patterns and correlations that could lead to new biomarker discoveries [92].

Personalized medicine approaches: AI and bioinformatics can also contribute to personalized medicine approaches by identifying subpopulations within sepsis patients based on their molecular profiles. This stratification can help tailor treatments to individual patients, improving outcomes and minimizing adverse reactions.

Drug repurposing and target identification: AI and bioinformatics can aid in drug repurposing by analyzing databases of known drugs and their mechanisms of action. This approach can identify potential drug candidates that could be effective in treating sepsis, accelerating the drug development process and reducing costs compared to developing new drugs from scratch.

Validation and verification: Once potential biomarkers are identified, AI and bioinformatics can assist in validating and verifying their efficacy using large datasets and statistical models. These tools can help assess the accuracy, specificity, and sensitivity of the biomarkers, ensuring that only the most promising candidates move forward to clinical validation.

Streamlining clinical trials: AI and bioinformatics can optimize clinical trial design and execution, making them more efficient and cost-effective. For instance, AI can simulate clinical trials, predicting patient outcomes and identifying the most suitable patient populations for enrollment.

Precision medicine strategies: AI and bioinformatics can support precision medicine strategies by incorporating genomic, epigenetic, and transcriptomic data to better understand patient variability and tailor treatments to individual responses [93].

Continuous learning and improvement: AI and machine learning algorithms can continuously learn from real-world data, adapting to changes in patient populations, treatment protocols, and emerging scientific knowledge. This enables a feedback loop where biomarker discovery and validation are refined over time, leading to improved diagnostic accuracy and patient outcomes [94].

IX. Conclusion:

Sepsis-induced respiratory dysfunction is a serious clinical concern associated with significant morbidity and mortality. This review synthesizes current knowledge on the intricate mechanisms, from direct lung injury to indirect systemic inflammation, that contribute to conditions like ARDS in sepsis patients. Identifying those at high risk and promptly intervening with appropriate antibiotics, lung-protective ventilation, and hemodynamic support are crucial for mitigating respiratory complications. Emerging tools utilizing genomics, biomarkers, and artificial intelligence hold immense promise for early diagnosis and personalized preventive strategies. Taken together, an integrated approach combining molecular research, clinical management, and translational bioinformatics is key to unraveling the pathogenesis, improving early detection, and developing innovative therapies to transform care and reduce the burden of sepsis-related respiratory complications.

X. Recommendations

Further research should focus on comprehensively elucidating the molecular pathways and genetic determinants influencing susceptibility to sepsis-induced lung injury. This could aid in developing targeted immunomodulatory or anti-inflammatory therapies. Refining existing biomarkers and identifying novel indicators of early lung damage through multi-omics approaches can enable risk stratification and timely intervention. Machine learning and AI methodologies should be leveraged to rapidly analyze complex datasets and derive clinically valid diagnostic, prognostic, and predictive models. Translating cutting-edge tools like gene expression panels and nanotechnology platforms from bench to bedside can facilitate personalized care. Fostering integrated collabo-ration between laboratory scientists and clinicians will be pivotal in advancing impactful innovations to transform sepsis management and mitigate respiratory complications.

Abbreviations list:

- SIRS - Systemic inflammatory response syndrome **- ARDS -** Acute respiratory distress syndrome **- PCT –** Procalcitonin **- CRP -** C-reactive protein **- IL-6 -** Interleukin 6 **- ICU -** Intensive care unit **- MODS -** Multiple organ dysfunction syndrome **- DIC -** Disseminated intravascular coagulation **- PEEP -** Positive end-expiratory pressure **- PaO2 -** Partial pressure of arterial oxygen **- FiO2 -** Fraction of inspired oxygen **- VAP -** Ventilator-associated pneumonia **- ALI -** Acute lung injury **- ROS -** Reactive oxygen species **- RNS -** Reactive nitrogen species **- TLRs -** Toll-like receptors **- PAMPs -** Pathogen-associated molecular patterns **- DAMPs -** Damage-associated molecular patterns **- HMGB1 -** High mobility group box 1 **- NETs -** Neutrophil extracellular traps **- SOFA -** Sequential Organ Failure Assessment **- qSOFA -** Quick SOFA **- BNP -** Brain natriuretic peptide **- cTn -** Cardiac troponin **- KL-6 -** Krebs von den Lungen-6 **- MMP-7 -** Matrix metalloproteinase-7 **- miR –** microRNA **- SCCM -** Society of Critical Care Medicine **- ESICM -** European Society of Intensive Care Medicine

Declarations:

Ethics approval and consent to participate: Not Applicable

Consent for publication: Not Applicable

Availability of data and materials: all data are available and sharing is available as well as publication.

Competing interests: The authors hereby that they have no competing interests.

Funding: Corresponding author supplied all study materials. There was no further funding for this study.

Authors' contributions: The authors completed the study protocol and were the primary organizers of data collection and the manuscript's draft and revision process. Tamer A. Addissouky wrote the article and ensured its accuracy. All authors contributed to the discussion, assisted in designing the study and protocol and engaged in critical discussions of the draft manuscript. Lastly, the authors reviewed and confirmed the final version of the manuscript.

Acknowledgements: The authors thank all the researchers, editors, reviewers, and the supported universities that have done great

efforts on their studies. Moreover, we are grateful to the editors, reviewers, and reader of this journal.

References

1. Geyer-Roberts, E.; Lacatusu, D. A.; Kester, J.; Foster-Moumoutjis, G.; Sidiqi, M. (2023). Preventative Management of Sepsis-Induced Acute Respiratory Distress Syndrome in the Geriatric Population.
2. Gong, H.; Chen, Y.; Chen, M.-L.; Li, J.; Zhang, H.; Yan, S.; Chuanzhu Lv. (2022). Advanced Development and Mechanism of Sepsis-Related Acute Respiratory Distress Syndrome., 9.
3. Arora, J.; Mendelson, A. A.; Fox-Robichaud, A. Sepsis: (2023). Network Pathophysiology and Implications for Early Diagnosis., 324 (5), R613–R624.
4. Attwell, C.; Laurent Sauterel; Jöhr, J.; Piquilloud, L.; Thierry Kuntzer; Diserens, K. (2022). Early Detection of ICU-Acquired Weakness in Septic Shock Patients Ventilated Longer than 72 H., 22 (1).
5. Gai, X.; Wang, Y.; Gao, D.; Ma, J.; Zhang, C.; Wang, Q. (2022). Risk Factors for the Prognosis of Patients with Sepsis in Intensive Care Units., 17 (9), e0273377–e0273377.
6. Schuurman, A. R.; P.M.A. Sloot; W. Joost Wiersinga; (2023). Tom. Embracing Complexity in Sepsis. 27 (1).
7. Yoshihara, I.; Kondo, Y.; Okamoto, K.; Tanaka, H. (2023). Sepsis-Associated Muscle Wasting: A Comprehensive Review from Bench to Bedside., 24 (5); 5040–5040.
8. Vincent, J.-L. (2022). Current Sepsis Therapeutics., 86, 104318–104318.
9. Czempik, P. F.; Wiórek, A. (2023). Management Strategies in Septic Coagulopathy: A Review of the Current Literature. Healthcare, 11 (2); 227.
10. Prescott, H. C.; Ostermann, M. (2023). What Is New and Different in the 2021 Surviving Sepsis Campaign Guidelines.
11. Nojood Basodan; Mehmadi, A.; Mehmadi, A.; Aldawood, S. M.; Ashraf Hawsawi; Fahad Fatini; et al. Septic Shock: Management and Outcomes. 2022.
12. Ashton, R.; Philips, B. E.; Faghy, M. A. (2023). The Acute and Chronic Implications of the COVID-19 Virus on the Cardiovascular System in Adults: A Systematic Review., 76, 31–37.
13. Adil Abalkhail; Thamer Alslamah. (2022). Institutional Factors Associated with Infection Prevention and Control Practices Globally during the Infectious Pandemics in Resource-Limited Settings., 10 (11), 1811–1811.
14. T A Addissouky, A E El Agroudy, A A Khalil, (2023). Developing a Novel Non-invasive Serum-based Diagnostic Test for Early Detection of Colorectal Cancer, *American Journal of Clinical Pathology*, Volume 160, Issue Supplement_1, November, Page S17.
15. Addissouky TA, El Tantawy El Sayed I, Ali MMA, Wang Y, El Baz A, Khalil AA, et al. (2023). Can Vaccines Stop Cancer Before It Starts? Assessing the Promise of Prophylactic Immunization Against High-Risk Preneoplastic Lesions J Cell Immunol.;5(4):127-126.
16. T A Addissouky, A A Khalil, (2020). Detecting Lung Cancer Stages Earlier by Appropriate Markers Rather Than Biopsy and Other Techniques, *American Journal of Clinical Pathology*, Volume 154, Issue Supplement_1, October, Pages S146–S147,
17. Colantuono, G.; Pardini, A.; (2023). Camila Antunes Lima. The Impact of Comorbidities and COVID-19 on the Evolution of Community Onset Sepsis., 13 (1).
18. Bai, L.; Huang, J.; Wang, D.; Zhu, D.; Zhao, Q.; Li, T.; Zhou, X.; Xu, Y. (2023).Association of Body Mass Index with Mortality of Sepsis or Septic Shock: An Updated Meta-Analysis., 11 (1).
19. Miranda, M.; Nadel, S. Pediatric Sepsis: (2023). A Summary of Current Definitions and Management Recommendations., 11 (2), 29–39.
20. Oami, T.; Imaeda, T.; Nakada, T.; Abe, T.; Takahashi, N.; Yamao, Y.; et al. (2023). Mortality Analysis among Sepsis Patients in and out of Intensive Care Units Using the Japanese Nationwide Medical Claims Database: A Study by the Japan Sepsis Alliance Study Group. Journal of Intensive Care, 11(1).
21. Carolina Lorencio Cárdenas; Juan Carlos Yébenes; Vela, E.; Montserrat Clèries; Josep Ma Sirvent; Fuster-Bertolín, C.; Reina, C.; et al. (2022). Trends in Mortality in Septic Patients according to the Different Organ Failure during 15 Years., 26 (1).
22. Nazer, L.; Lopez-Olivo, M. A.; Cuenca, J.; Awad, W.; Anne Rain Brown; Aseel Abusara; et al. (2022). All-Cause Mortality in Cancer Patients Treated for Sepsis in Intensive Care Units: A Systematic Review and Meta-Analysis., 30 (12), 10099–10109.
23. Xu, C., Zheng, L., Jiang, Y. et al. (2023). A prediction model for predicting the risk of acute respiratory distress syndrome in sepsis patients: a retrospective cohort study. BMC Pulm Med 23, 78 .
24. Keim G, Percy AG, Himebauch AS, et al. (2023). Acute respiratory failure-related excess mortality in pediatric sepsis Thorax Published.
25. Li, Q., Zheng, H. & Chen, B. (2023). Identification of macrophage-related genes in sepsis-induced ARDS using bioinformatics and machine learning. Sci Rep 13, 9876.
26. Addissouky, T.A., Sayed, I.E.T.E., Ali, M.M.A. et al. (2024). Latest advances in hepatocellular carcinoma management and prevention through advanced technologies. Egypt Liver Journal 14, 2.
27. Addissouky TA, Ali MMA, El Tantawy El Sayed I, Wang Y, El Baz A, Elarabany N, et al. (2023). Preclinical Promise and Clinical Challenges for Innovative Therapies Targeting Liver Fibrogenesis. Arch Gastroenterol Res.;4(1):14-23.
28. Addissouky, T.A., Wang, Y., Megahed, F.A.K. et al. (2021). Novel biomarkers assist in detection of liver fibrosis in HCV patients. Egypt Liver Journal 11, 86.
29. Addissouky, T.A., Ayman E. El-Agroudy, Abdel Moneim A.K. El-Torgoman and 1Ibrahim E. (2019). El-Sayed, Efficacy of Biomarkers in Detecting Fibrosis Levels of Liver Diseases. IDOSI Publications, World Journal of Medical Sciences, Volume 16, Issue (1): PP. 11-18, March, ISSN 1817-3055.
30. Addissouky, T.A., Ayman E. El Agroudy, Abdel Moneim A.K. El-Torgoman, Ibrahim El Tantawy El Sayed, (2019). Eman Mohamad Ibrahim, Efficiency of alternative markers to assess liver fibrosis levels in viral hepatitis B patients, Allied Academies Publications, Biomedical Research, Volume 30, Issue (2): PP. 351-356, April; ISSN 0970 938X,
31. Addissouky, T.A., (2019). Detecting Liver Fibrosis by Recent Reliable Biomarkers in Viral Hepatitis Patients, American Journal of Clinical Pathology, Volume 152, Issue Supplement_1, October 2019, Page S85, published: 11 September.
32. El Agroudy, A. E., Elghareb, M. S., Addissouky, T. A., Elshahat, E. H., & Hafez, E. H. (2016). Serum hyaluronic acid as a non-invasive biomarker to predict liver fibrosis in viral hepatitis patients. Journal of Biochemical and Analytical Research, 43(2), 108377.
33. El Agroudy, A. E., Elghareb, M. S., Addissouky, T. A., Elshahat, E. H., & Hafez, E. H. (2016). Biochemical study of some non-invasive markers in liver fibrosis patients. Journal of Biochemical and Analytical Research, 43(2), 108375.
34. Liu, Y.; Deng, S.; Song, Z.; Zhang, Q.; Guo, Y.; Yu, Y.; Wang, Y.; Li, T.; Fayed; Addissouky, T. A.; Mao, J.; Zhang,

Y. (2021). MLIF Modulates Microglia Polarization in Ischemic Stroke by Targeting EEF1A1. *Frontiers in Pharmacology*, *12*.

35. T A Addissouky, A A Khalil, A E El Agroudy, (2023). Assessment of potential biomarkers for early detection and management of Glomerulonephritis patients with diabetic diseases, *American Journal of Clinical Pathology*, Volume 160, Issue Supplement_1, November, Pages S18–S19,
36. Addissouky TA, Ali M, El Tantawy El Sayed I, Wang Y. (2023). Revolutionary Innovations in Diabetes Research: From Biomarkers to Genomic Medicine. IJDO; 15(4) :228-242
37. Ahlström, B., Frithiof, R., Larsson, IM. et al. (2022). A comparison of impact of comorbidities and demographics on 60-day mortality in ICU patients with COVID-19, sepsis and acute respiratory distress syndrome. Sci Rep 12, 15703.
38. Chang, Y.-M.; Chou, Y.-T.; Kan, W.-C.; Shiao, C.-C. (2022). Sepsis and Acute Kidney Injury: A Review Focusing on the Bidirectional Interplay. International Journal of Molecular Sciences, 23 (16), 9159–9159.
39. Bezati, S.; Velliou, M.; Ioannis Ventoulis; Panagiotis Simitsis; Parissis, J.; Polyzogopoulou, E. (2023). Infection as an Under-Recognized Precipitant of Acute Heart Failure: Prognostic and Therapeutic Implications. Heart Failure Reviews, 28(4), 893–904.
40. W. Joost Wiersinga; Tom. (2022). Immunopathophysiology of Human Sepsis. EBioMedicine, 86, 104363–104363.
41. Cusack, R.; Bos, J.; Póvoa, P.; Martin-Loeches, I. (2023). Endothelial Dysfunction Triggers Acute Respiratory Distress Syndrome in Patients with Sepsis: A Narrative Review. Frontiers in Medicine ,10.
42. Powell, R. E.; Kennedy, J.; Senussi, M. H.; Barbash, I. J.; Seymour, C. W. (2022). Association between Preexisting Heart Failure with Reduced Ejection Fraction and Fluid Administration among Patients with Sepsis. JAMA network open, 5 (10), e2235331–e2235331.
43. Merx, M. W.; Weber, C. (2007).Sepsis and the Heart. Circulation, 116 (7), 793–802.
44. Lalitha, A. V.; Pujari, C. G.; John Michael Raj; Ananya Kavilapurapu. (2022). Epidemiology of Acute Respiratory Distress Syndrome in Pediatric Intensive Care Unit: Single-Center Experience. Indian Journal of Critical Care Medicine, 26(8), 949–955.
45. Xu, C.; Zheng, L.; Jiang, Y.; Jin, L. (2023). A Prediction Model for Predicting the Risk of Acute Respiratory Distress Syndrome in Sepsis Patients: A Retrospective Cohort Study. BMC Pulmonary Medicine, 23 (1).
46. Vantini, C.; Matheus Negri Boschiero; Augusto, F. (2023). Epidemiological Profile and Risk Factors Associated with Death in Patients Receiving Invasive Mechanical Ventilation in an Adult Intensive Care Unit from Brazil: A Retrospective Study. Frontiers in Medicine ,10.
47. Schiavello, M.; Vizio, B.; Bosco, O.; Emanuele Pivetta; Mariano, F.; Montrucchio, G.; Lupia, E. (2023). Extracellular Vesicles: New Players in the Mechanisms of Sepsis- and COVID-19-Related Thromboinflammation. International Journal of Molecular Sciences, 24 (3);1920–1920.
48. Nong, Y.; Wei, X.; Yu, D. (2023). Inflammatory Mechanisms and Intervention Strategies for Sepsis-Induced Myocardial Dysfunction. Immunity, inflammation and disease, 11(5).
49. Englert, J. A.; Bobba, C.; Baron, R. M. Integrating molecular pathogenesis and clinical translation in sepsis-induced acute respiratory distress syndrome. Jci.org.
50. Bao, Y.; Zhu, X. (2022). Role of Chemokines and Inflammatory Cells in Respiratory Allergy. Journal of Asthma and Allergy, Volume 15, 1805–1822.
51. Zhu, W.; Zhang, Y.; Wang, Y. (2022). Immunotherapy Strategies and Prospects for Acute Lung Injury: Focus on Immune Cells and Cytokines. Frontiers in Pharmacology, 13.
52. Korbecki, J.; Agnieszka Maruszewska; Bosiacki, M.; Dariusz Chlubek; Baranowska-Bosiacka, I. (2022). The Potential Importance of CXCL1 in the Physiological State and in Noncancer Diseases of the Cardiovascular System, Respiratory System and Skin. International Journal of Molecular Sciences, 24 (1); 205–205.
53. Bhagat, A.; Pramesh Sunder Shrestha; Kleinerman, E. S. (2022). The Innate Immune System in Cardiovascular Diseases and Its Role in Doxorubicin-Induced Cardiotoxicity. International Journal of Molecular Sciences, 23(23); 14649–14649.
54. Aruna Jangam; Satya Krishna Tirunavalli; Bala Manikantha Adimoolam; BHAVANA KASIREDDY; Samata Sai Patnaik; Erukkambattu Jayashankar; et al. (2023). Anti-Inflammatory and Antioxidant Activities of Gymnema Sylvestre Extract Rescue Acute Respiratory Distress Syndrome in Rats via Modulating the NF-KB/MAPK Pathway. Inflammopharmacology, 31(2), 823–844.
55. Korkmaz, F.; Traber, K. (2023). Innate Immune Responses in Pneumonia. Pneumonia ,15(1).
56. Dominik Jarczak; Kluge, S.; Axel Nierhaus. (2021). Sepsis—Pathophysiology and Therapeutic Concepts. Frontiers in Medicine, 8.
57. Mayow, A. H.; Ahmad, F.; Muhammad Sohaib Afzal; Muhammad Usama Khokhar; Rafique, D.; Sai Krishna Vallamchetla; et al. (2023). A Systematic Review and Meta-Analysis of Independent Predictors for Acute Respiratory Distress Syndrome in Patients Presenting with Sepsis. Cureus.
58. Zarbock, A.; Nadim, M. K.; Pickkers, P.; Gomez, H.; Bell, S.; Joannidis, M.; et al. (2023). Sepsis-Associated Acute Kidney Injury: Consensus Report of the 28th Acute Disease Quality Initiative Workgroup. Nature Reviews Nephrology, 19 (6);401–417.
59. Battaglini, D.; Lou'i Al-Husinat; Gabriela, A.; Adriana Paes Leme; Franchini, K. G.; Morales, M. M.; et al. (2022). Personalized Medicine Using Omics Approaches in Acute Respiratory Distress Syndrome to Identify Biological Phenotypes. Respiratory Research, 23(1).
60. Nattachai Anantasit; Pharsai Prasertsan; (2023).Suchanuch Walanchapruk; Koonkoaw Roekworachai; Rujipat Samransamruajkit; Jarin Vaewpanich. Sepsis-Related Pediatric Acute Respiratory Distress Syndrome: A Multicenter Prospective Cohort Study. Turkish journal of emergency medicine ,0 (0).
61. Mannes, P. Z.; Barnes, C. E.; Biermann, J.; Latoche, J. D.; Day, K. E.; Zhu, Q.; et al. (2023). Molecular Imaging of Chemokine-like Receptor 1 (CMKLR1) in Experimental Acute Lung Injury. Proceedings of the National Academy of Sciences of the United States of America,120(3).
62. Miranda, M.; Nadel, S. Septic Shock: (2023). Early Rapid Recognition and Ongoing Management. Paediatrics and child health, 33(5);134–143.
63. Miranda, M.; Nadel, S. (2023). Pediatric Sepsis: A Summary of Current Definitions and Management Recommendations. Current Pediatrics Reports, 11(2); 29–39.
64. Schlapbach, L. J.; Zimmermann, E. A.; Meylan, S.; Stocker, M.; Suter, P. M.; Jakob, S. M.; on. (2023). Swiss Sepsis National Action Plan: A Coordinated National Action Plan to Stop Sepsis-Related Preventable Deaths and to Improve the Support of People Affected by Sepsis in Switzerland. Frontiers in Medicine;10.

65. Ronco, C.; Chawla, L. S.; Faeq Husain-Syed; Kellum, J. A. (2023). Rationale for Sequential Extracorporeal Therapy (SET) in Sepsis. Critical Care, 27(1).
66. Marques, A.; Torre, C.; Pinto, R.; Sepodes, B.; José Antonio Rocha. (2023). Treatment Advances in Sepsis and Septic Shock: Modulating Pro- and Anti-Inflammatory Mechanisms. Journal of Clinical Medicine, 12 (8); 2892–2892.
67. Takahashi, N.; Taro Imaeda; Nakada, T.; Takehiko Oami; Abe, T.; Yasuo Yamao; et al. (2022). Short- versus Long-Course Antibiotic Therapy for Sepsis: A Post Hoc Analysis of the Nationwide Cohort Study. DOAJ (DOAJ: Directory of Open Access Journals), 10(1).
68. Blerina Asllanaj; Benge, E.; Bae, J.-E.; McWhorter, Y. (2023). Fluid Management in Septic Patients with Pulmonary Hypertension, Review of the Literature. Frontiers in Cardiovascular Medicine; 10.
69. Addissouky TA, El Tantawy El Sayed I, Ali MMA, Wang Y, El Baz A, Elarabany N, et al. (2024). Shaping the Future of Cardiac Wellness: Exploring Revolutionary Approaches in Disease Management and Prevention. *J Clin Cardiol.;*5(1):6-29.
70. Sweeney, D. A.; Malhotra, A. (2022). Supportive Care in Patients with Critical Coronavirus Disease 2019. Infectious Disease Clinics of North America, 36 (4); 777–789.
71. Zhang, R.; Liu, H.; Dai, D.; Ding, X.; Wang, D.; Wang, Y.; et al. (2022). Adjunctive Sepsis Therapy with Aminophylline (STAP): A Randomized Controlled Trial. Chinese Medical Journal, 135(23), 2843–2850.
72. Guan, J.; Liao, Y.; Guo, Y.; Yu, S.; Wei, R.; Niu, M.; et al. (2022). Adjunctive Granisetron Therapy in Patients with Sepsis or Septic Shock (GRANTISS): A Single-Center, Single-Blinded, Randomized, Controlled Clinical Trial. Frontiers in Pharmacology, 13.
73. Go Oun Kim; Dong Ho Park; Bae, J.-S. (2023). Procyanidin B2 Attenuates Sepsis-Induced Acute Lung Injury via Regulating Hippo/Rho/PI3K/NF-KB Signaling Pathway. International Journal of Molecular Sciences, 24 (9); 7930–7930.
74. Seitaro Fujishima. (2023). Guideline-Based Management of Acute Respiratory Failure and Acute Respiratory Distress Syndrome. Journal of intensive care, 11(1).
75. Garduno, A.; Cusack, R.; Leone, M.; Einav, S.; Martin-Loeches, I. (2023). Multi-Omics Endotypes in ICU Sepsis-Induced Immunosuppression., 11(5); 1119–1119.
76. Wang, Y.; Yang, F.; Jiang, Y.; Wang, E. L.; Song, Y.; Chen, H *Microorganisms*.; et al. (2023). New Target for Molecular Hydrogen Therapy in Sepsis-Related Lung Injury Based on Proteomic and Genomic Analysis. International Journal of Molecular Sciences, 24 (14), 11325–11325.
77. Guo, G.; Wang, Y.; Kou, W.; Gan, H. (2022). Identifying the Molecular Mechanisms of Sepsis-Associated Acute Kidney Injury and Predicting Potential Drugs. Frontiers in Genetics, 13.
78. Gao, L.; Rafaels, N.; Dudenkov, T. M.; Mahendra Damarla; Damico, R.; Maloney, J. P.; et al. (2023). Xanthine Oxidoreductase Gene Polymorphisms Are Associated with High Risk of Sepsis and Organ Failure. Respiratory Research, 24 (1).
79. Li, Q.; Zheng, H.; Chen, B. (2023). Identification of Macrophage-Related Genes in Sepsis-Induced ARDS Using Bioinformatics and Machine Learning. Scientific Reports, 13(1).
80. Ishaque, S.; (2023). Stephen Thomas Famularo; Ali Faisal Saleem; Siddiqui, N.; Kazi, Z.; Sadia Parkar; et al. Biomarker-Based Risk Stratification in Pediatric Sepsis from a Low-Middle Income Country. Pediatric Critical Care Medicine, 24 (7), 563–573.
81. Sun, L.; Chen, Z.; Ni, Y.; He, Z. (2023). Network Pharmacology-Based Approach to Explore the Underlying Mechanism of Sinomenine on Sepsis-Induced Myocardial Injury in Rats. Frontiers in Pharmacology, 14.
82. Addissouky, T.A., et al. (2020). efficiency of mixture of olive oil and figs as an antiviral agent: a review and perspective, International Journal of Medical Science and Health Research, ISSN:2581-3366, Volume 4, Issue 4, Aug, page 107-111.
83. T A Addissouky, A A Khalil, A E El Agroudy, (2023). Assessing the Efficacy of a Modified Triple Drug Regimen Supplemented with Mastic Gum in the Eradication of Helicobacter pylori Infection, American Journal of Clinical Pathology, Volume 160, Issue Supplement_1, November, Page S19,
84. Pei, F.; Yao, R.; Ren, C.; Bahrami, S.; Billiar, T. R.; Chaudry, I. H.; et al. (2022). Expert Consensus on the Monitoring and Treatment of Sepsis-Induced Immunosuppression. Military Medical Research, 9 (1).
85. Song, C.; Xu, J.; Gao, C.; Zhang, W.; Fang, X.; Shang, Y. (2022). Nanomaterials Targeting Macrophages in Sepsis: A Promising Approach for Sepsis Management. Frontiers in Immunology, 13.
86. Addissouky TA, Ali MMA, El Tantawy El Sayed I, Wang Y. (2023). Recent Advances in Diagnosing and Treating Helicobacter pylori through Botanical Extracts and Advanced Technologies. Arch Pharmacol Ther.;5(1):53-66.
87. Addissouky, T.A., Wang, Y., El Sayed, I.E. et al. (2023). Recent trends in Helicobacter pylori management: harnessing the power of AI and other advanced approaches. Beni-Suef Univ J Basic Appl Sci 12, 80.
88. Zhang, G.; Luo, L.; Zhang, L.; Liu, Z. (2023). Research Progress of Respiratory Disease and Idiopathic Pulmonary Fibrosis Based on Artificial Intelligence. Diagnostics, 13 (3); 357–357.
89. Komorowski, M.; Green, A.; Tatham, K.; Seymour, C. W.; Antcliffe, D. (2022). Sepsis Biomarkers and Diagnostic Tools with a Focus on Machine Learning. Spiral (Imperial College London), 86, 104394–104394.
90. Chen, K.; Zhu, Y.; Xie, X.; Wu, J.; (2023). Qian, M. Six Potential Biomarkers in Septic Shock: A Deep Bioinformatics and Prospective Observational Study. Frontiers in Immunology, 14.
91. Mansur, A.; Vrionis, A.; Charles, J.; K. Hancel; Panagides, J.; Farzad Moloudi; Iqbal, S.; Daye, D. (2023). The Role of Artificial Intelligence in the Detection and Implementation of Biomarkers for Hepatocellular Carcinoma: Outlook and Opportunities. Cancers, 15(11),2928–2928.
92. Li, Y.; Tam, W.; Yu, Y.; Zhang, Z.; Xue, Z.; Tsang, C.-M.; et al. (2023). The Application of Aptamer in Biomarker Discovery. Biomarker research, 11 (1).
93. Choi, H.; Jin Young Lee; Yoo, H.; Jeon, K. (2023). Bioinformatics Analysis of Gene Expression Profiles for Diagnosing Sepsis and Risk Prediction in Patients with Sepsis. International Journal of Molecular Sciences, 24 (11), 9362–9362.
94. Qiu, S.; Cai, Y.; Ye, H.; Lin, C.; Xie, Y.; Tang, S.-Q.; Zhang, A. (2023). Small Molecule Metabolites: Discovery of Biomarkers and Therapeutic Targets. Signal Transduction and Targeted Therapy, 8 (1).
95.

DOI:10.31579/2693-2156/081